In the Q2, Aspira Women S Health Inc 's corporate clients experienced a reduction by -1.25 % in their costs of revenue, compared to a year ago, sequentially costs of revenue were trimmed by -6 %. During the corresponding time, Aspira Women S Health Inc saw a revenue deteriorated by -99.04 % year on year, sequentially revenue fell by -99.67 %. While revenue at the Aspira Women S Health Inc 's corporate clients recorded rose by 19.73 % year on year, sequentially revenue grew by 15.04 %.
Customers of Aspira Women S Health Inc saw their costs of revenue decrease by -1.25 % in Q2 compare to a year ago, sequentially costs of revenue were trimmed by -6 %, for the same period Aspira Women S Health Inc revnue deteriorated by -99.04 % year on year, sequentially revenue fell by -99.67 %.
Aspira Women S Health Inc's Comment on Sales, Marketing and Customers
The company provides services to physicians, physician office laboratories, and national and regional laboratories in the United States. Specimens are sent directly to the company, which handles billing to third-party payers or clients. The company maintains laboratory reference agreements and collaborations with Aspira Labs, Quest Diagnostics, ARUP, BioReference, Cleveland Clinic Foundation, and Mayo Clinic. These agreements enable access to Ova1 and OvaWatch testing services through health system and commercial laboratories, gynecologists, and women's healthcare providers nationwide. Additionally, the company offers access to its assays through decentralized technology transfer relationships with authorized distributors. Customers and markets include ARUP, Aspira Labs, BioReference, Cleveland Clinic Foundation, Mayo Clinic, and Quest Diagnostics.
Aspira Women S Health Inc’s Comment on Sales, Marketing and Customers
The company provides services to physicians, physician office laboratories, and national and regional laboratories in the United States. Specimens are sent directly to the company, which handles billing to third-party payers or clients. The company maintains laboratory reference agreements and collaborations with Aspira Labs, Quest Diagnostics, ARUP, BioReference, Cleveland Clinic Foundation, and Mayo Clinic. These agreements enable access to Ova1 and OvaWatch testing services through health system and commercial laboratories, gynecologists, and women's healthcare providers nationwide. Additionally, the company offers access to its assays through decentralized technology transfer relationships with authorized distributors. Customers and markets include ARUP, Aspira Labs, BioReference, Cleveland Clinic Foundation, Mayo Clinic, and Quest Diagnostics.
Sources:
Aspira Women s Health inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aspira Women s Health inc’s corporate clients.
For your research, we’ve provided 9 tables on Aspira Women s Health inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
23605.88 %
3.69 % 